Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avutometinib + defactinib + everolimus
- Development stage
- Unknown
- Lead developer
- Verastem Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This triplet combination therapy consists of avutometinib (a RAF/MEK clamp), defactinib (a focal adhesion kinase inhibitor), and everolimus (an mTOR inhibitor). Avutometinib, also known as VS-6766, inhibits the RAS/MAPK signaling pathway by binding to both RAF and MEK proteins, effectively clamping them in an inactive state. Defactinib targets focal adhesion kinase (FAK) to potentially overcome resistance mechanisms in the tumor microenvironment. Everolimus inhibits the PI3K/AKT/mTOR pathway. This combination is being investigated in a Phase Ib dose escalation and expansion study led by M.D. Anderson Cancer Center for patients with recurrent RAS pathway mutant endometrial cancer, aiming to evaluate safety, tolerability, and the recommended Phase 2 dose.
- Brand names
- Afinitor
- Other names
- VS-6766 + VS-6063 + everolimus
02
Targets
FKBP1AMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)FAK (Focal adhesion kinase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PTK2BMEK2 (Dual specificity mitogen-activated protein kinase kinase 2)RAF1 (c-Raf-1 (Y340D/Y341D))Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on avutometinib + defactinib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avutometinib + defactinib + everolimus.